Sweetener stevioside is a safe sugar substituteDecember 23, 2004Stevioside, the main sweet component in the leaves of the Stevia plant, tastes about 300 times sweeter than table sugar, which means only a small amount is needed for sweetening purposes. As the incidence of type-2 diabetes and obesity is sharply increasing, stevioside is an excellent substitute for sugar. The annual cost of treating these diseases is estimated at 5 billion euros in Belgium, 30 billion euros in Germany and 300 billion US dollars in the USA. However, the European Commission in 2000 refused to approve Stevia and stevioside because of insufficient evidence for their safety. Now an international team of scientists, led by Jan Geuns and Johan Buyse of the Katholieke Universiteit Leuven (K.U.Leuven, Belgium), has published a book in which they prove that stevioside is completely safe for use as a sweetener. Stevioside has numerous benefits as a sweetener: it is 100% natural, stable, contains no calories and promotes good dental health by reducing sugar intake. It can be used by diabetics, obese persons and patients suffering from phenylketonuria, an illness which requires a strict diet without artificial sweeteners such as aspartame. High concentrations of stevioside (250 mg three times daily) lower the blood pressure of hypertensive patients without affecting the blood biochemistry. No significant adverse effects have been observed, and stevioside intake does not affect male potency. It also has potential as a treatment for type-2 diabetes. Stevia and stevioside are permitted as food additives in Brazil, Korea and Japan. In the United States, they are permitted as a dietary supplement. In response to the European Commission's request for more research, K.U.Leuven professors Jan Geuns (Laboratory for Functional Biology) and Johan Buyse (Laboratory of Physiology and Immunology of Domestic Animals) set up the European Stevia Research Centre in 2003 at K.U.Leuven in order to co-ordinate research on Stevia and stevioside. One of the centre's goals is to develop a European quality label for stevioside, which should lead eventually to the lifting of the European ban on stevioside. The European Stevia Research Centre held the first international symposium on the safety of stevioside in April, 2004. Foreign specialists and K.U.Leuven scientists were invited to give an overview of the recent stevioside research and discussed amongst others the effects of stevioside on type-2 diabetes and on healty volunteers. The proceedings of the symposium, edited by professors Jan Geuns and Johan Buyse, are now available, and the general conclusion is that the use of stevioside as a sweetener is completely safe. The "Proceedings of the first symposium on the Safety of Stevioside" are available from: Euprint, Parkbosstraat 3, 3001 Heverlee, Belgium, e-mail: info@euprint.be. Website European Stevia Research Centre: http://www.kuleuven.ac.be/bio/biofys/ESC/ESC.htm Katholieke Universiteit Leuven |
|||||||||||||||||||||
| Related Diabetes Current Events and Diabetes News Articles Flaxseed oil and osteoporosis Animal studies suggest that adding flaxseed oil to the diet could reduce the risk of osteoporosis in post-menopausal women and women with diabetes, according to a report to be published in the International Journal of Food Safety, Nutrition and Public Health. Diabetes surgery summit consensus lays foundation for new field of medicine A first-of-its-kind consensus statement on diabetes surgery is published online today in the Annals of Surgery. ESC to give talks on Diabetes in three cities in China As a result of successful events organised last year, a second Joint Scientific Forum, organised by the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD), two of the most respected professional medical organisations in Europe, will be held from 27-29 November at three venues across China - Beijing, Shanghai and Guangzhou. New research shows versatility of amniotic fluid stem cells For the first time, scientists have demonstrated that stem cells found in amniotic fluid meet an important test of potential to become specialized cell types, which suggests they may be useful for treating a wider array of diseases and conditions than scientists originally thought. First reconstitution of an epidermis from human embryonic stem cells Stem cell research is making great strides. This is yet again illustrated by a study carried out by the I-STEM* Institute (I-STEM/ Inserm UEVE U861/AFM), published in the Lancet on 21 November 2009. The I-STEM team, directed by Marc Peschanski has just succeeded in recreating a whole epidermis from human embryonic stem cells. An atomic-level look at an HIV accomplice Since the discovery in 2007 that a component of human semen called SEVI boosts infectivity of the virus that causes AIDS, researchers have been trying to learn more about SEVI and how it works, in hopes of thwarting its infection-promoting activity. Scripps research scientists find new link between insulin and core body temperature A team led by scientists at The Scripps Research Institute have discovered a direct link between insulin-a hormone long associated with metabolism and metabolic disorders such as diabetes-and core body temperature. Scientists find molecular trigger that helps prevent aging and disease Researchers at Mount Sinai School of Medicine set out to address a question that has been challenging scientists for years: How do dietary restriction-and the reverse, overconsumption-produce protective effects against aging and disease? Pivotal study for PSD502 -- the first potential treatment for premature ejaculation At the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC ("Plethora" - AIM:PLE)., today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE). Night Beat, Overtime and a Disrupted Sleep Pattern Can Harm Officers' Health A police officer who works the night shift, typically from 8 p.m. to 4 a.m., already is at a disadvantage when it comes to getting a good "night's" sleep. More Diabetes Current Events and Diabetes News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||